Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 5:43 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–11 of 11 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Galera Therapeutics, Inc. Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Effects of Renal Impairment on the Pharmacokinetics, Safety and Tolerability of GC4419

NCT05412472
View directory record Official record
Conditions
Renal Impairment
Interventions
GC4419
Drug
Lead sponsor
Galera Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
2
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 9, 2022 · Synced Oct 7, 2026, 5:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Absorption, Metabolism, Excretion, and Mass Balance of GC4419 in Healthy Adult Subjects

NCT03163173
View directory record Official record
Conditions
Healthy Volunteers, Healthy
Interventions
GC4419
Drug
Lead sponsor
Galera Therapeutics, Inc.
Industry
Eligibility
19 Years to 55 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Nov 17, 2017 · Synced Oct 7, 2026, 5:43 AM EDT
Completed Phase 1 Interventional

A Phase 1 Dose Escalation Study of GC4419 in Combination With Chemoradiation for Squamous Cell Cancer of the Head & Neck

NCT01921426
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Oral Cavity, Squamous Cell Carcinoma of the Oropharynx
Interventions
GC4419
Drug
Lead sponsor
Galera Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
10
States / cities
Lakeland, Florida • Iowa City, Iowa • St Louis, Missouri + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2016 · Synced Oct 7, 2026, 5:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Effects of 90 mg Intravenous Infusions of GC4419 on the Single Dose Pharmacokinetics of Dextromethorphan in Healthy Adult Subjects

NCT03792971
View directory record Official record
Conditions
Healthy
Interventions
Dextromethorphan HBr, GC4419
Drug
Lead sponsor
Galera Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 19, 2019 · Synced Oct 7, 2026, 5:43 AM EDT
Completed Phase 3 Interventional Results available

ROMAN: Phase 3 Trial Investigating the Effects of GC4419 on Radiation Induced Oral Mucositis in Head/Neck Cancer Patients

NCT03689712
View directory record Official record
Conditions
Oral Mucositis
Interventions
GC4419 90mg, Placebo
Drug
Lead sponsor
Galera Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
455 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
86
States / cities
Gilbert, Arizona • Jonesboro, Arkansas • Corona, California + 77 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2023 · Synced Oct 7, 2026, 5:43 AM EDT
Completed Phase 2 Interventional Results available

A Study of the Effects of GC4419 on Radiation Induced Oral Mucositis in Patients With Head/Neck Cancer

NCT02508389
View directory record Official record
Conditions
Radiation Induced Oral Mucositis
Interventions
Low Dose GC4419: 30mg/day, High Dose GC4419: 90mg/day, Placebo, Intensity-Modulated Radiation Therapy, Cisplatin
Drug · Radiation
Lead sponsor
Galera Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
60
States / cities
Phoenix, Arizona • Tucson, Arizona • Jonesboro, Arkansas + 55 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2021 · Synced Oct 7, 2026, 5:43 AM EDT
Terminated Phase 2 Interventional Results available

Phase 2b Study of GC4711 in Combination With SBRT for Nonmetastatic Pancreatic Cancer

NCT04698915
View directory record Official record
Conditions
SBRT, Borderline Resectable Pancreatic Cancer, Unresectable Pancreatic Cancer
Interventions
Drug GC4711, Placebo
Drug
Lead sponsor
Galera Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
21
States / cities
Gilbert, Arizona • Los Angeles, California • Miami, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated May 21, 2024 · Synced Oct 7, 2026, 5:43 AM EDT
Terminated Phase 2 Interventional Results available

A Trial of GC4419 in Patients With Critical Illness Due to COVID-19

NCT04555096
View directory record Official record
Conditions
Covid19, SARS-CoV-2 Infection
Interventions
GC4419, Placebo
Drug
Lead sponsor
Galera Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
3
States / cities
Iowa City, Iowa • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 18, 2022 · Synced Oct 7, 2026, 5:43 AM EDT
Terminated Phase 2 Interventional Results available

Effects of Intravenous GC4419 on the Incidence and Severity of Esophagitis Due to Chemoradiotherapy for Lung Cancer

NCT04225026
View directory record Official record
Conditions
Esophagitis
Interventions
GC4419 (avasopasem manganese)
Drug
Lead sponsor
Galera Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
12
States / cities
Gilbert, Arizona • Tampa, Florida • Columbus, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2023 · Synced Oct 7, 2026, 5:43 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Pilot Dose Escalation Trial of Stereotactic Body Radiation Therapy (SBRT) in Combination With GC4419 in Pancreatic Cancer

NCT03340974
View directory record Official record
Conditions
Pancreatic Cancer, Stereotactic Body Radiation Therapy
Interventions
GC4419, Placebo, Stereotactic Radiation Therapy (SBRT) 50 Gy, Stereotactic Radiation Therapy (SBRT) 55 Gy
Drug · Radiation
Lead sponsor
Galera Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
6
States / cities
Tampa, Florida • Boston, Massachusetts • Morristown, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2023 · Synced Oct 7, 2026, 5:43 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Phase I/II Study of SBRT and GC4711 for Centrally Located or Large NSCLC

NCT04476797
View directory record Official record
Conditions
SBRT, NSCLC, Non-metastatic
Interventions
GC4711 +SBRT, Placebo +SBRT
Drug
Lead sponsor
Galera Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
10
States / cities
Greeley, Colorado • Loveland, Colorado • Columbus, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2024 · Synced Oct 7, 2026, 5:43 AM EDT